Skip 
Navigation Link
Medical Disorders
Resources
Basic InformationLookupsLatest News
Black Children Missing Out on Eczema TreatmentNew Framework Guides Tx Decisions for Atopic DermatitisHealth Tip: Recognizing SepsisAround the World, Too Little Relief for PainNearly 4 in 10 U.S. Adults Now ObeseFDA Panel Supports Gene Therapy for Kids With Rare Eye Disease30-Day Mortality Lower With Female SurgeonsDirect Primary Care May Fill Niche for Uninsured3 Factors That Could Raise Your Risk of Bloodstream InfectionStroke Risk Factors Are RisingTwo Ebola Vaccines Spur Lasting Immune ResponseHormone Therapy May Be OK for Women With MigrainesMigraine MattersMedial Temporal Lobe Surgery Linked to Prevalence of TinnitusHigher Levels of Fungus ID'd in Patients With Crohn'sWhere There's Type 1 Diabetes, Celiac Disease May FollowAntibiotic Use Not Linked to Islet, Celiac Disease AutoimmunitySome U.S. Olympians Got West Nile in Brazil, But Not ZikaPenicillin Misconceptions May Raise Post-Op Infection RiskHate UTIs? One Simple Step Can Cut the RiskIDSA: Retail Meat May Be a Transmission Source for UTIsLonger Anesthesia Duration Tied to More Surgical ComplicationsFirst Test to Detect Zika in Blood Donations ApprovedHealth Tip: Learn Symptoms of Childhood SinusitisLimiting 'Cold Time' Could Make More Organs Available for TransplantHealth Literacy Linked to Length of Stay After Abdominal SurgeryZika Vaccine Works in Early Human TrialHealth Tip: Understanding Loud Noise and Hearing LossAllergy Relief Do's and Don'tsPatient Factors Differ for Surgical, All-Cause ReadmissionComing Soon: A Faster Test for Antibiotics Against UTIs?Antibody Injections in Pregnancy Might Shield Fetus From ZikaHealth Tip: Giving BloodMore U.S. Measles Cases From No Vaccine vs. Imported DiseaseHigh Epsom Salt Intake Can Lead to Severe Liver InjuryTattoo Pigment Hypersensitivity Can Mimic LymphomaObesity Linked to 13 Types of CancerBlood Thinners Can Come With Dangerous Side EffectsMeasles Making a Comeback in the United StatesAfter Deepwater Oil Cleanup in Gulf, Ill Effects PersistState Laws Can Promote Hepatitis C Virus ScreeningHow Much Alcohol Is Really OK?Girls' Sports-Related Concussions May Last Twice As LongSingle Mutation Made Zika Virus More VirulentVi-Tetanus Toxoid Conjugate Vaccine Can Prevent TyphoidDialysis Patients Often End Up Back in the HospitalRespiratory Disease Death Rates Have SoaredGenetic Tweaks in Mosquitoes Might Curb Malaria TransmissionImmunochromatography Testing Differentiates Dengue, ZikaFDA Approves New Continuous Glucose Monitor for Diabetes
Questions and AnswersLinksBook Reviews
Related Topics

Researchers Target Zolmitriptan Dosing for Pediatric Migraine


HealthDay News
Updated: Jun 8th 2017

new article illustration

THURSDAY, June 8, 2017 (HealthDay News) -- In a report published online June 5 in the Journal of Clinical Pharmacology, recommended dosing regimens of zolmitriptan are suggested for children with migraine.

Wangda Zhou, Ph.D., from AstraZeneca Pharmaceuticals in Waltham, Mass., and colleagues developed a population pharmacokinetic model for zolmitriptan and its active metabolite in adults and adolescents, and provided appropriate dosing regimens for use in clinical trials in 6- to 11-year-old children. Data from a single-dose study involving 5.0-mg zolmitriptan nasal spray (ZNS) conducted in adult and adolescents with migraine were applied.

The researchers found that adults and adolescents had similar plasma concentration profiles of zolmitriptan and its metabolite 183C91. The estimated typical apparent volume of distribution and clearance of zolmitriptan were 136 L and 121 L/h, respectively; between-subject variability was 56.5 and 42.6 percent, respectively. To achieve exposures similar to those of the adult and adolescent population administered 5.0 mg ZNS, a body-weight dosing scheme of 5.0 and 2.5 mg ZNS is recommended in children greater than and less than 50 kg, respectively.

"The recommended doses for children to achieve exposure similar to that observed in adults given 2.5 mg ZNS are 2.5 mg (≥50 kg) and 1.0 mg (15 to 50 kg)," the authors write. "These dosing regimens could be used in future clinical trials."

The authors disclosed financial ties to AstraZeneca, a manufacturer of zolmitriptan.

Abstract
Full Text (subscription or payment may be required)